Biomune Systems Inc. announces first quarter earnings results and appointment of new director.SALT LAKE CITY--(BUSINESS WIRE)--Feb. 27, 1995--Biomune Systems Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BIME) Monday announced first quarter fiscal 1995 earnings results. During the three months ended Dec. 31, 1994, the company had revenues of $83,043 compared to $82,734 for the comparable three month period ended Dec. 31, 1993. The net loss applicable to common shares increased from $603,157, or 5 cents per common share, for the three months ended Dec. 31, 1993, to $995,815, or 6 cents per common share, for the three months ended Dec. 31, 1994. The increase in net loss is primarily attributable to the increased level of activity in developing the company's Immune Technology, as well as the accrual of dividends in the amount of $32,721 on the company's Series A and Series B Preferred Stock Stock shares that have preferential rights to dividends or to amounts distributable on liquidation, or to both, ahead of common shareholders. Preferred stock is given preference over common stock. Holders of preferred stock receive dividends at a fixed annual rate. . The company expects to incur a net loss for fiscal year 1995. The company also announced the appointment of Christopher D. Illick to the board of directors. "Mr. Illick will clearly be an asset to the current board and will bring a wealth of financial expertise that will compliment the science and business experience of the existing board members," stated David G. Derrick derrick: see crane. Derrick famous hangman; eponym of modern hoisting apparatus. [Br. Hist.: Espy, 170] See : Execution , president of Bioumune Systems Inc. Illick is a founding and general partner of Illick Brothers and the managing director of Helios Co., a financial services The examples and perspective in this article or section may not represent a worldwide view of the subject. Please [ improve this article] or discuss the issue on the talk page. firm. He was a founder and the president of the U.S. subsidiary of Robert Fleming Robert Fleming is the name of:
For approximately 15 years, Illick effected corporate finance transactions and identified investment opportunities for Fleming's clients in the U.K., Europe, the Far East and the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . Illick has been a member of the board of directors of many corporations, including Intersil, Loehmann's, National Transaction Network and Biotechnology General. He holds a Bachelor of Arts degree from Trinity College Trinity College, Ireland: see Dublin, Univ. of. Trinity College Private liberal arts college in Hartford, Conn., founded in 1823. It is historically affiliated with the Episcopal church, though its curriculum is nonsectarian. and a LL.B degree from the University of Virginia Law School. Biomune Systems Inc. is a biotechnology company engaged in the research and development of an immune technology designed to enhance the body's own ability to fight disease. For additional information, contact Joy M. Erickson at 801/582-2345. CONTACT: Biomune Systems Inc., Salt Lake City Joy M. Erickson, 801/582-2345 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion